These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 6338979)

  • 21. A simple method for detection of human factor IX inhibitor using ELISA.
    Takamiya O; Kinoshita S
    Scand J Clin Lab Invest; 1997 Dec; 57(8):683-8. PubMed ID: 9458490
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Alloantibodies in hemophilia B binding to multiple factor IX epitopes.
    Thompson AR
    Thromb Res; 1987 Apr; 46(1):169-74. PubMed ID: 2438804
    [No Abstract]   [Full Text] [Related]  

  • 23. Characterization and experimental use of a monospecific antiserum to factor IX.
    Pechet L; Tiarks CY; Chang CH; Sudhindra RR; Lipworth L
    Thromb Haemost; 1979 Feb; 40(3):455-64. PubMed ID: 106483
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Extracorporeal immunoadsorption for the treatment of haemophilic patients with inhibitors to factor VIII or IX.
    Knöbl P; Derfler K
    Vox Sang; 1999; 77 Suppl 1():57-64. PubMed ID: 10529691
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Functional mapping of anti-factor IX inhibitors developed in patients with severe hemophilia B.
    Christophe OD; Lenting PJ; Cherel G; Boon-Spijker M; Lavergne JM; Boertjes R; Briquel ME; de Goede-Bolder A; Goudemand J; Gaillard S; d'Oiron R; Meyer D; Mertens K
    Blood; 2001 Sep; 98(5):1416-23. PubMed ID: 11520790
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use of proteomics for validation of the isolation process of clotting factor IX from human plasma.
    Clifton J; Huang F; Gaso-Sokac D; Brilliant K; Hixson D; Josic D
    J Proteomics; 2010 Jan; 73(3):678-88. PubMed ID: 19819359
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Monoclonal antibodies to factor IX: characterization and use in immunoassays for factor IX.
    Smith KJ; Ono K
    Thromb Res; 1984 Jan; 33(2):211-24. PubMed ID: 6422579
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Purification and characterization of rabbit factor IX and its existence as a two-chain factor IX alpha in circulating plasma.
    Rao LV; Hoang AD
    Thromb Res; 1991 Oct; 64(1):57-68. PubMed ID: 1776139
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Coagulation Factor IX concentrate: method of preparation and assessment of potential in vivo thrombogenicity in animal models.
    Menache D; Behre HE; Orthner CL; Nunez H; Anderson HD; Triantaphyllopoulos DC; Kosow DP
    Blood; 1984 Dec; 64(6):1220-7. PubMed ID: 6498336
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preparation of factor IX deficient human plasma by immunoaffinity chromatography using a monoclonal antibody.
    Goodall AH; Kemble G; O'Brien DP; Rawlings E; Rotblat F; Russell GC; Janossy G; Tuddenham EG
    Blood; 1982 Mar; 59(3):664-70. PubMed ID: 7059674
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Purification of human factor IX by chromatography of a coagulation factor concentrate.
    Suomela H
    Thromb Haemost; 1976 Feb; 35(1):211-21. PubMed ID: 989188
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Studies on immunological assay of vitamin-K dependent factors. III. A double monoclonal immunoradiometric assay for factor IX antigen.
    Mikami S; O'Brien DP; Mellars G; Goodall AH; Tuddenham EG
    Br J Haematol; 1986 Mar; 62(3):513-24. PubMed ID: 3485443
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Partial factor IX protein in a pedigree with hemophilia B due to a partial gene deletion.
    Bray GL; Thompson AR
    J Clin Invest; 1986 Apr; 77(4):1194-200. PubMed ID: 3514676
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A simplified procedure for purification of human prothrombin, factor IX and factor X.
    Bajaj SP; Rapaport SI; Prodanos C
    Prep Biochem; 1981; 11(4):397-412. PubMed ID: 7312833
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The isolation of prothrombin, Factor IX and Factor X from human Factor IX concentrates.
    Modi GJ; Blajchman MA; Ofosu FA
    Thromb Res; 1984 Dec; 36(6):537-47. PubMed ID: 6084874
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characterization of the defect in activation of factor IX Chapel Hill by human factor XIa.
    Braunstein KM; Noyes CM; Griffith MJ; Lundblad RL; Roberts HR
    J Clin Invest; 1981 Dec; 68(6):1420-6. PubMed ID: 6976355
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A standardized method for measuring anti-F VIII: C inhibitors in haemophilia A by coagulation inhibition in agarose gel.
    Jorquera JI; Carmona E; Aznar JA; Peiró A; Sánchez-Cuenca JM
    Thromb Haemost; 1985 Aug; 54(2):377-80. PubMed ID: 3936211
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Measurement of anti-factor IX IgG subclasses in haemophilia B patients who developed inhibitors with episodes of allergic reactions to factor IX concentrates.
    Sawamoto Y; Shima M; Yamamoto M; Kamisue S; Nakai H; Tanaka I; Hayashi K; Giddings JC; Yoshioka A
    Thromb Res; 1996 Aug; 83(4):279-86. PubMed ID: 8870172
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A procedure for removing high titer antibodies by extracorporeal protein-A-sepharose adsorption in hemophilia: substitution therapy and surgery in a patient with hemophilia B and antibodies.
    Nilsson IM; Jonsson S; Sundqvist SB; Ahlberg A; Bergentz SE
    Blood; 1981 Jul; 58(1):38-44. PubMed ID: 7236891
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Assay of factor IX antigen using an enzyme immuno assay.
    Parquet-Gernez A; Mazurier C; Amiral J; Martinoli JL
    Thromb Res; 1984 Sep; 35(6):703-12. PubMed ID: 6506026
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.